NRC FORM 374

PAGE 1 of 3 PAGES Amendment No. 45

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee			In accordance with application dated						
				July 24, 201					
1. Mallinckrodt, LLC			3. License No. 24-04206-05MD						
	· · · ·					tirety to read as follows:			
2. 2703 Wagner Place Maryland Heights, Missouri 63043				 Expiration Date: July 31, 2022 Docket No. 030-10801 					
	roduct, source, and/or specia lear material	l 7. Cher	nical and/or physica	al form		imum amount that licensee may sess at any one time under this ise			
Α.	lodine-131	Α.	Sodium Iodide (NDA 16-517)	I-131 capsules	Α.	Not applicable			
В.	lodine-131	B .	Sodium Iodide solution (NDA		В.	Not applicable			
C .	Molybdenum- 99/Technetium-99m	C.	Molybdenum-99 99m generators Ultra-TechneKo Eluting DTE at TechneKow™ (NDA No. 17-2	s [Mallinckrodt ow™ Dry Top nd Ultra- V4 Generators	C.	No single generator to exceed 19.0 curies at the time of shipment			
D.	Indium-111	D.	Indium Chlorid solution (NDA 2 841)	e In-111 sterile 20-314 and 19-	D.	Not applicable			
E.	Thallium-201	Ε.	Thallous Chlorie solution (NDA	de TI-201 sterile 18-150)	Ε.	Not applicable			
F.	Gallium-67	F.	Gallium Citrate solution (NDA		F.	Not applicable			
G.	lodine-123	G.	Sodium lodide absorbed into s gelatin capsule and NDA 17-91	sucrose within a (NDA 17-909	G.	Not applicable			

NRC	FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION								
-			License No. 24-04206-05MD							
		IATERIALS LICENSE UPPLEMENTARY SHEET	Docket or Reference No. 030-10801							
			Amendment No. 45							
			L							
9.	Authorized Use	r.								
	Pursuant to Section 32.72 and 32.74 of 10 CFR Part 32, the licensee is authorized to distribute the byproduct material described in Items 6 and 7 of this license to persons licensed pursuant to Sections 35.100, 35.200 and 35.300 of 10 CFR Part 35, or under equivalent licenses of Agreement States, for the Sections indicated below:									
	A. and B. Sections 35.100, 35.200 or 35.300.									
	C. Section 35.200 or for distribution to commercial nuclear pharmacies.									
	D. through G.	Sections 35.100 or 35.200.								
		CONDITIONS								
10.	 Each product distributed under this license shall not contain, as of the assay date (labeled size at calibration), more than the quantity of byproduct material listed in the table contained in Attachment I to the licensee's application dated July 24, 2014. 									
11.	. The licensee may distribute material from the licensee's facilities located at 2703 Wagner Place, Maryland Heights, Missouri.									
12	2. This license does not authorize possession or use of licensed material.									
	. 1871	그 같이 있는 것이 아이지 않는 것을 가 없다. 것은 것을 가 없다. 것은 것은 것은 것을 가 없다. 것은 것은 것은 것은 것은 것을 가 없다. 것은 것은 것은 것은 것은 것을 가 없다. 것은 것을 가 없다. 것은								
13.	The Radiation S	Safety Officer (RSO) for this license is Scot	tt J. Surovi.							
14.	The licensee shall notify the U.S. Nuclear Regulatory Commission within thirty (30) days of the termination of a "Notice of Claimed Investigational Exemption for a New Drug (IND) for licensed material described in Items 6 and 7.									
15.	The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."									
16.	6. Any proposed change to shielding that will increase the radiation levels of the packaging shall be submitted to the NRC for review. Any proposed change to labeling that will cause a change to radioactive markings or labeled activity, other than position and increasing the size of symbols and wording, shall be submitted to NRC for review.									

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	3	PAGES
		License No. 24-04206-05MD	-				
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference No. 030-10801					
		Amendment No. 45					

- 17. Except as specifically provided otherwise by this license, the licensee shall manufacture, package, label and distribute licensed material described in Items 6 and 7 of this license and conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Applications dated March 5, 2013 (re: labeling revisions), January 21, 2014 (with attached letters dated January 17 and 21, 2014), and July 24, 2014; and
 - B. Letters dated April 28, 2011 (with attachments), February 7, 2012 (with attachments), August 30, 2012, January 15, 2013 (with attached application dated January 16, 2013), January 21, 2013 (RSO acceptance), February 13, 2013, March 5, 2013 (re: RSO position and org charts), July 11, 2013 (including attached SEC Form 8-K dated June 28, 2013) and July 18, 2013.

Bv

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Bryan A. Þarker Materials Licensing Branch Region III

Date

OCT 23 2014